https://mindmedicinelaw.com/briefing/ketamine-s-short-term-efficacy-for-sud-a-meta-analysis-insight-20260717-23626The Psychedelic Journalen2026-07-19T15:04:47.086532+00:00Ketamine's Short-Term Efficacy for SUD: A Meta-Analysis Insightketamine, substance use disorder, meta-analysis, clinical trials, short-term efficacy, safety concerns, treatment protocols, neuroscience, public health, randomized controlled trialshttps://mindmedicinelaw.com/briefing/fda-fast-tracks-psychedelic-research-following-executive-order-20260717-23744The Psychedelic Journalen2026-07-19T15:04:06.928167+00:00FDA Fast-Tracks Psychedelic Research Following Executive OrderFDA, psychedelic research, executive order, clinical trials, mental health, drug approval, Compass Pathways, Healing Pharmaceuticals, market dynamics, policy shifthttps://mindmedicinelaw.com/briefing/spiritual-concerns-in-psychedelic-therapy-for-palliative-care-20260717-23314The Psychedelic Journalen2026-07-18T22:05:08.244609+00:00Spiritual Concerns in Psychedelic Therapy for Palliative Carepsychedelic therapy, spiritual support, palliative care, existential distress, psilocybin, MDMA, LSD, ketamine, clinical trials, narrative reviewhttps://mindmedicinelaw.com/briefing/uk-s-divergent-policies-on-psychedelics-and-assisted-suicide-drugs-20260717-23315The Psychedelic Journalen2026-07-18T22:05:00.498920+00:00UK's Divergent Policies on Psychedelics and Assisted Suicide DrugsUK drug policy, psychedelics regulation, assisted suicide drugs, drug rescheduling, clinical trials, regulatory standards, mental health treatment, policy implications, ethical considerationshttps://mindmedicinelaw.com/briefing/ketamine-psychedelics-in-depression-current-evidence-future-directions-20260717-23328The Psychedelic Journalen2026-07-18T15:06:07.944904+00:00Ketamine & Psychedelics in Depression: Current Evidence & Future Directionsketamine, esketamine, psilocybin, depression treatment, treatment-resistant depression, rapid-acting antidepressants, NMDA receptor antagonist, neuroplasticity, serotonergic mechanisms, glutamatergic modulationhttps://mindmedicinelaw.com/briefing/publication-bias-in-psilocybin-depression-trials-implications-20260717-23294The Psychedelic Journalen2026-07-18T15:05:57.302997+00:00Publication Bias in Psilocybin Depression Trials: Implicationspsilocybin, depression, publication bias, randomized controlled trials, Bayesian meta-analysis, therapeutic potential, clinical trials, research transparency, effect size, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-and-psychedelics-in-depression-treatment-a-review-20260717-23329The Psychedelic Journalen2026-07-18T15:05:48.278524+00:00Ketamine and Psychedelics in Depression Treatment: A Reviewketamine, esketamine, psilocybin, treatment-resistant depression, rapid-acting antidepressants, neuroplasticity, NMDA receptor antagonist, serotonergic mechanisms, glutamatergic modulation, psychedelic therapyhttps://mindmedicinelaw.com/briefing/federal-investigation-targets-online-ketamine-sales-20260716-23747The Psychedelic Journalen2026-07-19T15:04:56.652769+00:00Federal Investigation Targets Online Ketamine Salesketamine, online sales, federal investigation, psychedelic regulation, DEA, FDA, controlled substances, public health, market impact, legal compliancehttps://mindmedicinelaw.com/briefing/ethical-considerations-in-neurotechnology-development-20260716-23330The Psychedelic Journalen2026-07-18T22:05:14.963789+00:00Ethical Considerations in Neurotechnology Developmentneurotechnology, ethics, user-centered design, consumer exploitation, patient care, neuroethics, communication asymmetries, responsible innovation, policy implications, societal impacthttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-neural-avalanches-new-insights-20260716-23331The Psychedelic Journalen2026-07-18T15:06:24.651496+00:00Psilocybin's Impact on Neural Avalanches: New Insightspsilocybin, neural avalanches, brain dynamics, psychedelic research, EEG analysis, therapeutic potential, spatiotemporal structure, optimal transport, dynamic time warping, PsiConnect studyhttps://mindmedicinelaw.com/briefing/psychedelic-therapies-for-ptsd-mdma-s-emerging-role-20260716-23317The Psychedelic Journalen2026-07-18T15:06:16.731735+00:00Psychedelic Therapies for PTSD: MDMA's Emerging RoleMDMA-assisted therapy, psychedelic therapies, PTSD treatment, neuroplasticity, fear extinction, standardized protocols, public health, psychedelics, clinical trials, treatment-resistant PTSDhttps://mindmedicinelaw.com/briefing/fda-schedules-hearing-on-psychedelics-for-medical-use-20260715-23743The Psychedelic Journalen2026-07-19T15:04:19.577472+00:00FDA Schedules Hearing on Psychedelics for Medical UseFDA hearing, psychedelic therapies, medical approval, psilocybin, MDMA, mental health treatment, regulatory pathways, clinical trials, safety concerns, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-therapy-for-veterans-faces-funding-challenges-20260715-22908The Psychedelic Journalen2026-07-17T22:05:03.811994+00:00Ketamine Therapy for Veterans Faces Funding Challengesketamine therapy, veterans, PTSD, depression, mental health, funding cuts, VA, glutamate system, antidepressant, policy implicationshttps://mindmedicinelaw.com/briefing/anchor-framework-s-role-in-psychedelic-assisted-therapy-20260715-22820The Psychedelic Journalen2026-07-17T22:04:54.981029+00:00ANCHOR Framework's Role in Psychedelic-Assisted Therapypsychedelic-assisted therapy, ANCHOR framework, facilitator competencies, therapeutic accompaniment, complex systems, psilocybin, integration, neuroscience, therapeutic alliance, ethicshttps://mindmedicinelaw.com/briefing/fda-clarifies-mdma-and-psilocybin-trial-guidelines-20260714-23746The Psychedelic Journalen2026-07-19T15:04:29.647583+00:00FDA Clarifies MDMA and Psilocybin Trial GuidelinesFDA guidelines, MDMA trials, psilocybin research, psychedelic therapies, clinical trials, regulatory framework, psychedelic industry, safety protocols, market approval, mental health treatmentshttps://mindmedicinelaw.com/briefing/gaba-ssris-combo-promising-depression-treatment-in-china-20260714-22792The Psychedelic Journalen2026-07-18T22:05:38.774991+00:00GABA+SSRIs Combo: Promising Depression Treatment in ChinaGABAergic agents, SSRIs, depression treatment, Shanghai Mental Health Center, PHQ-9 trajectory, combination pharmacotherapy, network pharmacology, clinical trialshttps://mindmedicinelaw.com/briefing/selenium-nanoparticles-show-promise-in-depression-treatment-20260714-22500The Psychedelic Journalen2026-07-18T22:05:31.825434+00:00Selenium Nanoparticles Show Promise in Depression Treatmentselenium nanoparticles, depression treatment, neuroinflammation, oxidative stress, social isolation, rat model study, neuroprotection, mental health, therapeutic avenues, neuroscience researchhttps://mindmedicinelaw.com/briefing/interprofessional-views-on-psychiatric-polypharmacy-practices-20260714-22822The Psychedelic Journalen2026-07-18T22:05:24.213475+00:00Interprofessional Views on Psychiatric Polypharmacy Practicespsychiatric polypharmacy, interprofessional collaboration, healthcare providers, psychiatrists, psychiatric nurses, pharmacists, mental health care, medication safety, patient outcomes, polypharmacy riskshttps://mindmedicinelaw.com/briefing/ptsd-treatment-preferences-psychedelics-vs-traditional-therapies-20260714-23318The Psychedelic Journalen2026-07-18T15:06:34.835529+00:00PTSD Treatment Preferences: Psychedelics vs. Traditional TherapiesPTSD treatment preferences, MDMA-assisted therapy, psychedelic-assisted therapy, traditional psychotherapy, clinical practice, mental health care, patient needs, treatment adherence, regulatory landscape, psychosocial factorshttps://mindmedicinelaw.com/briefing/challenges-in-schizophrenia-drug-discovery-animal-models-under-scrutiny-20260714-22824The Psychedelic Journalen2026-07-17T22:05:36.609953+00:00Challenges in Schizophrenia Drug Discovery: Animal Models Under Scrutinyschizophrenia research, animal models, drug discovery, human biomarkers, neurophysiology, clinical relevance, in vitro models, in silico models, collaboration, therapeutic developmenthttps://mindmedicinelaw.com/briefing/zero-prediction-errors-in-neural-processing-and-psychedelics-20260714-22825The Psychedelic Journalen2026-07-17T22:05:28.666350+00:00Zero Prediction Errors in Neural Processing and Psychedelicszero prediction errors, reinforcement learning, neural processing, psychedelic research, affect and belief updating, EEG analyseshttps://mindmedicinelaw.com/briefing/dmt-immersion-study-neuroscience-insights-and-limits-20260714-22903The Psychedelic Journalen2026-07-17T22:05:21.816800+00:00DMT Immersion Study: Neuroscience Insights and LimitsDMT, psychedelic research, consciousness, clinical applications, phenomenology, serotonin receptors, mental health, policy implications, psychedelic therapy, regulatory frameworkshttps://mindmedicinelaw.com/briefing/dietary-supplement-use-for-mood-in-poland-a-public-health-concern-20260714-22791The Psychedelic Journalen2026-07-17T22:05:11.782921+00:00Dietary Supplement Use for Mood in Poland: A Public Health Concerndietary supplements, mood improvement, stress relief, Poland, healthcare communication, nutrivigilance, patient education, drug interactions, public health, self-medicationhttps://mindmedicinelaw.com/briefing/fda-s-final-guidance-on-psychedelic-trials-key-changes-20260713-23742The Psychedelic Journalen2026-07-19T15:04:37.709334+00:00FDA's Final Guidance on Psychedelic Trials: Key ChangesFDA guidance, psychedelic trials, clinical research, regulatory framework, safety standards, therapeutic endpoints, risk management, informed consent, psychedelic therapies, public health